1st Quarter Sales Surpass Projections for BDI Pharma

Specialty biotech distributor announces 42% increase for FY2012 over the same period in 2011.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

BDI Pharma's Columbia, SC Headquarters

The fact that we were able to overcome those hurdles while generating double digit growth…is a testament to the quality and dedication of those individuals that constitute the exceptional staff at BDI Pharma.

Columbia, SC (PRWEB) April 20, 2012

BDI Pharma, Inc. (BDI), the nation’s fastest growing national distributor of biotech therapies, announced that Sales Revenues for the first quarter of its fiscal year (calendar year 2012) represented an increase of more than forty-two percent (42%) compared with the same period during calendar year 2011. This exceeded the company’s twenty-four percent (24%) projected growth and significantly outpaced the rate of twenty-nine percent (29%) recorded as the overall increase for 2011 over 2010.

In the 2012 to 2011 quarter-to-quarter analysis, the Specialty Biopharmaceutical class of products, specifically in the clinical areas of Oncology and Neurology more than doubled, representative of the continued success of the organization’s service-oriented, solution-based offering to the physician marketplace. The continuing expansion of BDI’s reach was not limited to one class of products, as the Protein Biotherapeutics, led by Immunology (66% increase) and Hemophilia (15% increase), represented considerable growth for the biotech distributor, as well.

The atmosphere within which this accomplishment was generated is of note. During this same time frame, BDI’s business and staff, throughout multiple departments, expanded and the company began the production, or “go live”, phase of its SAP business system implementation.

“Moving into the year with new trading partners, training on a vastly expanded product portfolio, adding substantially to staff and entering the final production phase of a new operating system would present numerous challenges to any growing organization,” stated William A. Shirey, III, Executive Vice President of BDI Pharma. “The fact that we were able to overcome those hurdles while generating double digit growth over this period is a testament to the quality and dedication of those individuals that constitute the exceptional staff at BDI Pharma, who, when faced with an unprecedented multitude of potential distractions, never wavered in their daily commitment to the organization’s ultimate objective – providing unparalleled service and value to the specialty biopharmaceutical marketplace.”

About BDI Pharma, Inc.

Since 1995, BDI Pharma has defined its customer-centric approach to serving the nation's healthcare community through innovative supply solutions, unparalleled customer service, extensive product knowledge, 24/7 emergency availability and urgent-need delivery. An open-access resource for reference material, educational literature, market data and online ordering, bdipharma.com (ivig.com) has become an industry-renowned point of reference. Proprietary programs for specialty veterinarians -- 4legpharma.com; product consignment -- consignadvantage.com; flu pre-booking and general vaccine ordering -- securivax.com; and purchasing/reward programs -- qoreprogram.com and securigam.com round out a family of solutions tailored to the needs of the healthcare community at large.

BDI Pharma’s portfolio includes branded and generic specialty biopharmaceuticals, chemotherapy products, vaccines, albumin, IVIG, coagulation factors, high-titer or “hyper” immune globulins, and other specialty injectables. BDI Pharma is recognized as an “ADR,” or Authorized Distributor of Record, for all of the manufacturers it represents.


Contact